(Q24248062)

7 August 2017

1 reference

title

Donepezil for dementia due to Alzheimer's disease (English)

1 reference

7 August 2017

1 reference

0 references

0 references

JS Birks

1

0 references

R Harvey

series ordinal

2

1 reference

PubMed ID

12917900

7 August 2017

J S Birks

series ordinal

1

1 reference

7 August 2017

21 July 2003

0 references

1 January 2003

1 reference

Cochrane Database of Systematic Reviews

7 August 2017

1 reference

7 August 2017

CD001190

1 reference

7 August 2017

3

1 reference

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

7 August 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Donepezil therapy in clinical practice: a randomized crossover study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Use of donepezil for the treatment of mild-moderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD001190

1 reference

7 January 2021

A new rating scale for dementia syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Bias in treatment assignment in controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Quantitative EEG changes in Alzheimer patients during long-term donepezil therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190

7 January 2021

10.1002/14651858.CD001190

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12917900